GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020
October 30 2020 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will
host a conference call and webcast to report its third quarter
financial results on Friday, November 6, 2020, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for
domestic participants or (216) 562-0466 for international
participants, with participant code 3073766. Participants are
encouraged to connect 15 minutes in advance of the call to ensure
that all callers are able to connect. A webcast replay will be
available via the “Investors” tab on the GlycoMimetics website for
30 days following the call. A dial-in phone replay will be
available for 24 hours after the close of the call by dialing
(855)-859-2056 for domestic participants and (404) 537-3406 for
international participants, participant code 3073766.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage
clinical development programs and a pipeline of novel glycomimetic
drugs, all designed to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role.
GlycoMimetics' drug candidate, uproleselan, an E-selectin
antagonist, was evaluated in a Phase 1/2 clinical trial as a
potential treatment for AML and is being evaluated across a range
of patient populations including a Company-sponsored Phase 3 trial
in relapsed/refractory AML under breakthrough therapy designation.
Rivipansel, a pan-selectin antagonist, is being explored for use in
treatment of acute VOC in SCD. GlycoMimetics has also completed a
Phase 1 clinical trial with another wholly-owned drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics
is located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
forward-looking statements include those relating to the planned or
potential clinical development of the Company’s product candidates,
including expectations with regard to the enrollment of patients in
its ongoing Phase 3 clinical trial of uproleselan and the Company’s
engagement with regulatory authorities, as well as the presentation
of data from preclinical studies and clinical trials and the
potential benefits and impact of the Company’s drug candidates.
Actual results may differ materially from those described in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the
Company’s annual report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on February 28, 2020, and other
filings GlycoMimetics makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201030005292/en/
Investor: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com Media: Jamie Lacey-Moreira Phone:
410-299-3310 Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024